1. Taiwan Stocks

  2. •

    Commercial services

  3. •

    Miscellaneous commercial services
SciVision Biotech Inc.

SciVision Biotech Inc.

TTWSE:1786
39.70
TWD
-0.15
(-0.38%)
2.31EPS
22.20P/E
3.93BMarket Cap
Oct 29Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
3.72
2.54
4.34
3.81
4.31
5.53
6.66
7.05
7.64
8.42
10.67
12.78
12.24
12.08
Basic EPS, GAAP
0.75
-0.36
0.9
-0.44
0.29
1.46
1.84
1.93
1.54
2.14
2.66
3.51
2.24
2.42
Free Cash Flow per Basic Share
0.18
-2
-2.55
-3.2
-5.14
0.27
0.04
0.9
1.1
2.52
3.85
3.4
0.31
0.71
Dividend per Share
- -
0.56
- -
0.43
- -
0.17
1.41
1.2
0.88
1.42
1.99
2.45
3.23
- -
Book Value per Share
17.43
17.74
15.55
14.91
15.24
17.46
20.56
21.21
21.9
22.83
24.02
26.42
26.46
24.42
Tangible Book Value per Share
17.41
17.72
15.52
14.8
15.15
17.37
20.47
21.15
21.85
22.79
23.99
26.4
26.45
24.4
Basic Weighted Avg Shares
54
62
61
60
60
60
66
66
66
66
67
69
72
74
Sales/Revenue/Turnover
201
158
265
228
258
330
438
467
506
557
713
883
887
889
Operating Margin (%)
14.87
-22.34
15.16
12.18
12.05
24.47
30.65
31.41
24.12
24.15
28
28.09
21.42
16.46
Depreciation Expense
23
19
20
21
21
21
15
15
53
62
63
65
80
88
Net Income, GAAP
40
-22
55
-26
17
87
121
128
102
142
178
242
162
178
Effective Tax Rate (%)
- -
- -
- -
- -
24.4
6.69
10.11
16.06
12.35
18.34
15.28
16.92
12.27
14.11
Profit Margin (%)
20.12
-13.99
20.71
-11.5
6.63
26.36
27.57
27.42
20.12
25.43
24.95
27.43
18.31
20.03
Working Capital
938
768
498
399
266
313
397
432
500
753
859
829
1,253
1,098
LT Debt
- -
- -
25
229
422
363
310
320
328
411
347
85
474
475
Total Equity
1,084
1,023
949
894
914
1,078
1,361
1,404
1,450
1,511
1,627
1,897
1,980
1,787
Return on Invested Capital (%)
- -
- -
- -
- -
1.8
5.13
7.54
7.2
5.59
5.46
8.63
10.02
7.24
5.92
Return on Capital (%)
- -
- -
- -
- -
1.55
6.1
7.93
7.89
5.71
7.33
9.48
12.06
7.38
8.9
Return on Common Equity (%)
5.37
-2.1
5.56
-2.85
1.9
8.72
9.9
9.26
7.13
9.57
11.34
13.75
8.37
10.16

Capital Structure

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
11
10
10
LT Borrowings
374
376
379
LT Finance Leases
101
98
97
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
75
75
73
Market Capitalization
5,432
4,677
3,929

Working Capital

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
1,427
1,527
1,299
Cash, Cash Equivalents & STI
1,054
1,092
906
Accounts Receivable, Net
240
288
220
Inventories
82
99
91
Total Current Liabilities
175
373
201
Payables & Accruals
- -
- -
- -
ST Debt
11
10
10
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
7.99%
7.22%
4.38%
Free Cash Flow
242.1%
21.28%
-90.54%
Net Income, GAAP
18.62%
9.5%
-32.99%
Sales/Revenue/Turnover
13.71%
14.14%
0.37%
Total Cash Common Dividend
- -
28.27%
38.12%

Quarterly Revenue

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
195
211
222
255
883
2025
204
209
221
251
887
2026
205
211
- -
- -
- -

Quarterly Earnings Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.76
1
0.82
0.92
3.51
2025
0.79
-0.22
0.81
0.87
2.24
2026
0.29
0.47
- -
- -
- -

Quarterly Dividends Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
2.45
2025
- -
- -
- -
- -
3.23
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Kai Cheng Han
Full Time Employees
1,947
Sector
Commercial services
Industry
Miscellaneous commercial services
Address
No. 1, South 1st Road Kaohsiung City KHH Taiwan 806
IPO Date
Dec 29, 2010
Website
scivision.com.tw
Similar Companies
PayPal Holdings, Inc. (NASDAQ:PYPL)
Shopify Inc. (NASDAQ:SHOP)
Greenland Mines Ltd (NASDAQ:GRML)
Block, Inc. (NYSE:XYZ)
Netcapital Inc. (NASDAQ:NCPL)
Shopify, Inc. Class A (TSX:SHOP)
Business
SciVision Biotech Inc. (1786.TW) manufactures and sells hyaluronic acid-based medical products utilizing its proprietary Cross-Linked Hyaluronic Acid Platform (CHAP) technology; core offerings include hyaluronic acid dermal fillers such as Hya-Dermis for facial aesthetics and plastic surgery, synovial fluid supplements like Hya-Joint for orthopedic joint cavity injections and knee osteoarthritis treatment, absorbable adhesion barriers for surgical applications, and intravesical instillation products for urology. The company also engages in wholesale of medical equipment and provides management consulting services. Founded in 2001 and headquartered in Kaohsiung, Taiwan, with production facilities in the Kaohsiung Cianjhen Technology Industrial Park compliant with ISO 13485, US FDA, and PIC/s GMP standards, SciVision Biotech operates in the Americas, Europe, Asia, Middle East, and Africa, serving medical, aesthetic, orthopedic, surgical, and urological markets. Recent developments include overseas market expansion into Russia, with hyaluronic acid dermal fillers contributing to revenue starting in the fourth quarter of 2025. The company maintains 64 employees and reported trailing twelve-month revenue of TWD 891.22 million and net income of TWD 163.57 million as of late 2025.